Pharma Mar S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
13,093.00
14,399.00
5,909.00
24,699.00
22,860.00
7,689
Depreciation, Depletion & Amortization
4,591.00
5,263.00
6,282.00
7,205.00
7,059.00
6,862
Other Funds
5,190.00
4,108.00
2,176.00
2.00
1,202.00
2,074
Funds from Operations
13,661.00
19,846.00
12,895.00
16,395.00
11,658.00
2,901
Changes in Working Capital
2,684.00
2,263.00
1,794.00
7,981.00
10,199.00
13,439
Net Operating Cash Flow
16,345.00
22,109.00
11,101.00
8,414.00
1,459.00
16,340
Capital Expenditures
2,095.00
10,179.00
9,221.00
6,093.00
4,665.00
Sale of Fixed Assets & Businesses
-
-
-
129.00
85.00
Purchase/Sale of Investments
12,099.00
12,807.00
-
-
-
Net Investing Cash Flow
10,828.00
22,312.00
28,325.00
13,779.00
5,995.00
Issuance/Reduction of Debt, Net
17,160.00
1,309.00
43.00
1,926.00
3,291.00
Net Financing Cash Flow
23,051.00
5,704.00
8,302.00
1,296.00
5,262.00
Net Change in Cash
4,122.00
5,907.00
8,922.00
6,661.00
9,798.00
Free Cash Flow
14,250.00
11,930.00
1,880.00
14,507.00
6,124.00
Other Sources
824.00
674.00
-
52,429.00
38,242.00
Change in Capital Stock
701.00
2,905.00
6,169.00
632.00
769.00
Other Uses
-
-
19,104.00
32,686.00
27,667.00

About Pharma Mar

View Profile
Address
Avenida de los Reyes, 1
Colmenar Viejo Madrid 28770
Spain
Employees -
Website http://www.pharmamar.es
Updated 07/08/2019
Pharma Mar SA is a biopharmaceutical holding company, which engages in discovery and development of innovative marine-derived anticancer drugs. It operates through the following segments: Oncology, Diagnostics, RNAi, and Consumer Chemicals. The Oncology segment encompasses the Group undertakings whose object is to research, develop and market anti-tumour drugs.